Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase” Jeong-Ju Yoo, Sang Gyune Kim Clinical and Molecular Hepatology.2023; 29(2): 513. CrossRef
Association of HBV serological markers with host antiviral immune response relevant hepatic inflammatory damage in chronic HBV infection Bei Jiang, Leijie Wang, Huan Liu, Lin Wang, Rui Su, Liang Xu, Guochao Wei, Jia Li, Fengmin Lu, Xiangmei Chen Journal of Medical Virology.2024;[Epub] CrossRef
Accurate prediction of HCC risk in patients with chronic HBV infection: HBeAg status and HBsAg level matter Jimmy Che-To Lai, Anna S.F. Lok Hepatology.2026; 83(1): 11. CrossRef
Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States Kevin Pak, Ryan Sachar, Sammy Saab Digestive Diseases and Sciences.2025; 70(4): 1547. CrossRef
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim Clinical and Molecular Hepatology.2023; 29(2): 482. CrossRef
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment? Wen-Juei Jeng, Grace Lai-Hung Wong Hepatology Communications.2023; 7(3): e0060. CrossRef
Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee Clinical and Molecular Hepatology.2023; 29(3): 794. CrossRef
A global investment case for hepatitis B elimination: a modelling study Christopher P Seaman, Phillip Luong, Yinzong Xiao, Romesh Abeysuriya, Jess Howell, Margaret Hellard, Nick Scott The Lancet Gastroenterology & Hepatology.2023; 8(10): 932. CrossRef
Correlation between contrast-enhanced ultrasound perfusion parameters and EphB4 expression in hepatocellular carcinoma lesions Chen-ZhuoYa Sheng, Gen-Xin Yao, Xin-Rong Zhang, Dong Li World Chinese Journal of Digestology.2021; 29(18): 1084. CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim Cancers.2021; 13(14): 3424. CrossRef
Background/Aims The immune-tolerant (IT) phase of chronic hepatitis B (CHB) patients is not generally indicative of antiviral therapy (AVT). We assessed and compared the risk of hepatocellular carcinoma (HCC) during the IT-phase stringently defined by a low fibrosis-4 (FIB-4) index, compared to that in patients undergoing AVT.
Methods Among 125 untreated patients that were hepatitis B e-antigen positive, hepatitis B virus-DNA >20,000 IU/mL, with normal alanine aminotransferase level from 2012 to 2018, those with a FIB-4 index of <1.45 were classified into the IT-group. The cumulative probability of HCC was estimated using Kaplan-Meier analysis. All patients were assessed until HCC development (intention-to-treat [ITT] analysis), whereas those suspected of experiencing CHB phase switch were assessed using the per-protocol (PP) and censored at the time of phase switch.
Result s: The cumulative probability of HCC at 1-, 3-, and 5-years among the IT-group was zero, compared to AVT-treated patients with FIB-4 indices <1.45 during the same period: 0.2%, 0.6%, and 1.4%, respectively (P=0.264 for ITT and P=0.533 for PP). Among the initially screened 125 untreated patients, those with a FIB-4 index of ≥1.45 had a higher risk of HCC compared to the IT-group (P=0.005). Furthermore, among AVT-treated patients, those with a FIB-4 index of ≥1.45 had a higher risk of HCC compared to their counterpart (P<0.001).
Conclusions The risk of HCC was negligible in the IT-group stringently defined by a low FIB-4 index. However, given that a higher HCC risk exists among untreated patients with higher FIB-4, appropriate criteria for AVT should be established.
Citations
Citations to this article as recorded by
Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: A systematic review and meta-analysis Jimmy Che-To Lai, Grace Lai-Hung Wong, Yee-Kit Tse, Vicki Wing-Ki Hui, Mandy Sze-Man Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Journal of Hepatology.2025; 82(6): 992. CrossRef
Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States Kevin Pak, Ryan Sachar, Sammy Saab Digestive Diseases and Sciences.2025; 70(4): 1547. CrossRef
Antiviral treatment response to nucleos(t)ide analogues in chronic hepatitis B patients with normal alanine aminotransferase levels: a retrospective multi-center study Fei Cao, Jian Wang, Ye Xiong, Ying Zhang, Xinrong Zhang, Tao Fan, Li Zhu, Shaoqiu Zhang, Zhiyi Zhang, Yifan Pan, Yuanyuan Li, Chao Jiang, Juan Xia, Yu Shi, Xiaomin Yan, Yuxin Chen, Xingxiang Liu, Chuanwu Zhu, Chao Wu, Rui Huang Emerging Microbes & Infections.2025;[Epub] CrossRef
Gray zone of hepatitis B virus infection Young-Suk Lim Saudi Journal of Gastroenterology.2024; 30(2): 76. CrossRef
Treatment decisions based on HBV DNA Young‐Suk Lim Journal of Viral Hepatitis.2024; 31(S2): 36. CrossRef
HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx Marc Ringelhan, Svenja Schuehle, Maarten van de Klundert, Elena Kotsiliti, Marie-Laure Plissonnier, Suzanne Faure-Dupuy, Tobias Riedl, Sebastian Lange, Karin Wisskirchen, Frank Thiele, Cho-Chin Cheng, Detian Yuan, Valentina Leone, Ronny Schmidt, Juliana H JHEP Reports.2024; 6(10): 101128. CrossRef
Viral Load–Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B Gi-Ae Kim, Young-Suk Lim, Seungbong Han, Gwang Hyeon Choi, Won-Mook Choi, Jonggi Choi, Dong Hyun Sinn, Yong-Han Paik, Jeong-Hoon Lee, Yun Bin Lee, Ju-Yeon Cho, Nae-Yun Heo, Man-Fung Yuen, Vincent Wai-Sun Wong, Stephen L. Chan, Hwai-I Yang, Chien-Jen Chen Annals of Internal Medicine.2024; 177(10): 1308. CrossRef
Canadian Association for the Study of the Liver Single Topic Conference on Hepatitis B Virus: ‘Progress toward hepatitis B elimination in Canada’ Julian Hercun, Golasa Samadi Kochaksaraei, Simmone D'souza, Rachel Talavlikar, Jennifer Van Gennip, Carla Osiowy, Carla S Coffin, Harley Crowshoe Canadian Liver Journal.2024; 7(3): 385. CrossRef
Management of antiviral treatment for chronic hepatitis B patients with high viral load Ken Lin, Su-Wen Jiang, Ai-Rong Hu World Chinese Journal of Digestology.2024; 32(9): 625. CrossRef
A nomogram based on HBeAg, AST, and age to predict non-minimal liver inflammation in CHB patients with ALT <80 U/L Lu Zhang, Xiaoyue Bi, Xiaoxue Chen, Luxue Zhang, Qiqiu Xiong, Weihua Cao, Yanjie Lin, Liu Yang, Tingting Jiang, Wen Deng, Shiyu Wang, Shuling Wu, Ruyu Liu, Yuanjiao Gao, Ge Shen, Min Chang, Hongxiao Hao, Mengjiao Xu, Leiping Hu, Yao Lu, Minghui Li, Yao Xi Frontiers in Immunology.2023;[Epub] CrossRef
Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis Han Ah Lee, Seung Up Kim, Yeon Seok Seo, Sang Hoon Ahn, Chai Hong Rim Hepatology Communications.2023; 7(2): e0011. CrossRef
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise Moon Haeng Hur, Jeong-Hoon Lee Clinical and Molecular Hepatology.2023; 29(2): 363. CrossRef
Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B? Joo Hyun Oh, Dong Hyun Sinn Clinical and Molecular Hepatology.2023; 29(2): 367. CrossRef
Research Progress on the Need for Antiviral Therapy in Chronic HBV Infected Patients with Normal ALT 益帆 胡 Advances in Clinical Medicine.2023; 13(04): 5360. CrossRef
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim Clinical and Molecular Hepatology.2023; 29(2): 482. CrossRef
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase” Chia-Ming Chu, Yun-Fan Liaw Clinical and Molecular Hepatology.2023; 29(2): 510. CrossRef
Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication Su-Wen Jiang, Xiang Lian, Ai-Rong Hu, Jia-Lin Lu, Zhe-Yun He, Xiao-Jun Shi, De-Dong Zhu, Zong-Yi Wang, Guan-Cheng Huang World Journal of Gastroenterology.2023; 29(16): 2479. CrossRef
Management of Immune-Tolerant Patients with Chronic HBV Infection Tai-Chung Tseng, Hung-Yao Lin, Jia-Horng Kao Current Hepatology Reports.2023; 22(3): 130. CrossRef
Global importance of new treatment strategies to efforts to control hepatitis B virus Carol Forbes, Louis Lavoie, Sacha Satram, Ling Shen, Vaidehi Thanawala, Andre Arizpe, Norah Terrault Expert Review of Anti-infective Therapy.2023; 21(8): 847. CrossRef
Chronic Hepatitis B Feng Su, Ira M. Jacobson Clinics in Liver Disease.2023; 27(4): 791. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
Early Treatment Consideration in Patients with Hepatitis B ‘e’ Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift? Apostolos Koffas, Lung-Yi Mak, Upkar S. Gill, Patrick T. F. Kennedy Viruses.2022; 14(5): 900. CrossRef
Genotypes Variation and Molecular Epidemiology Of The Hbv Chronic Liver Infection In The Local Population Of Pakistan: An Overview Of The Recent Literature Bushra Tahreem, Ghadir Ali, Haroon Ahmad, Asim Shahzad, Muhammad Khurram, Nabiha Naeem, Aquib Nazar, Muhammad Haris, Hassan ., Shahrukh . Pakistan BioMedical Journal.2022;[Epub] CrossRef
Surveillance for hepatocellular carcinoma: It is time to move forward Bo Hyun Kim, Yuri Cho, Joong-Won Park Clinical and Molecular Hepatology.2022; 28(4): 810. CrossRef
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong Clinical and Molecular Hepatology.2021; 27(2): 273. CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim Cancers.2021; 13(14): 3424. CrossRef
The natural history of chronic hepatitis B (CHB) is complex and may run through different immune phases that may overlap. In particulars, the immune-tolerant phase is the most interesting and not as well understood as we thought. The concept of true immune tolerance have been under challenged from immunology points of view. The major international guidelines have not yet reached a consensus on the definition of the immune-tolerant phase. While positive hepatitis B e antigen (HBeAg), high serum hepatitis B virus (HBV) DNA and normal serum alanine aminotransferase (ALT) levels are the three key features of this phase, some guidelines also put age into consideration. A new nomenclature, Phase 1 or HBeAg-positive chronic HBV infection, is given by the latest European Association for the Study of the Liver (EASL) published in April 2017. While current guidelines advise against starting antiviral treatment for immune-tolerant CHB patients, some new data suggest treating such patients may reduce the risk of liver fibrosis progression and hepatocellular carcinoma.
Citations
Citations to this article as recorded by
A state-of-the-art review of the recent advances in exosome isolation and detection methods in viral infection Amirsasan Gorgzadeh, Ahmad Nazari, Adnan Ali Ehsan Ismaeel, Diba Safarzadeh, Jawad A. K. Hassan, Saman Mohammadzadehsaliani, Hadis Kheradjoo, Pooneh Yasamineh, Saman Yasamineh Virology Journal.2024;[Epub] CrossRef
Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma Nevin Varghese, Amry Majeed, Suraj Nyalakonda, Tina Boortalary, Dina Halegoua-DeMarzio, Hie-Won Hann Cancers.2024; 16(4): 777. CrossRef
Management of Hepatitis B in Pregnancy Jeanette Rios, Lital Aliasi-Sinai, Natalia Schmidt, Tatyana Kushner Current Hepatology Reports.2024; 23(2): 278. CrossRef
A New Assessment of Two Transferase-Based Liver Enzymes in Low- and High-Fibrosis Patients Chronically Infected with Hepatitis B Virus: A Meta-Analysis and Pilot Study Marina Manea, Ion Mărunțelu, Ileana Constantinescu Journal of Clinical Medicine.2024; 13(13): 3903. CrossRef
A hierarchical multilabel graph attention network method to predict the deterioration paths of chronic hepatitis B patients Zejian (Eric) Wu, Da Xu, Paul Jen-Hwa Hu, Ting-Shuo Huang Journal of the American Medical Informatics Association.2023; 30(5): 846. CrossRef
Exosomal HBV-DNA for diagnosis and treatment monitoring of chronic hepatitis B Xu Xu, Li Zhang, Jiamin Liu, Xiangxin Kong, Yu Yin, Zhiwei Jia, Xiaoqin Zhang, Bin Peng, Min Ji, Wanlong Pan Open Life Sciences.2023;[Epub] CrossRef
Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B? Joo Hyun Oh, Dong Hyun Sinn Clinical and Molecular Hepatology.2023; 29(2): 367. CrossRef
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim Clinical and Molecular Hepatology.2023; 29(2): 482. CrossRef
Research Progress on the Need for Antiviral Therapy in Chronic HBV Infected Patients with Normal ALT 益帆 胡 Advances in Clinical Medicine.2023; 13(04): 5360. CrossRef
Chronic Hepatitis B Feng Su, Ira M. Jacobson Clinics in Liver Disease.2023; 27(4): 791. CrossRef
Hepatocellular Carcinoma and Hepatitis: Advanced Diagnosis and Management with a Focus on the Prevention of Hepatitis B-Related Hepatocellular Carcinoma Soo Ryang Kim, Soo Ki Kim Diagnostics.2023; 13(20): 3212. CrossRef
Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase Gyeol Seong, Dong Hyun Sinn, Wonseok Kang, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Yong-Han Paik European Journal of Gastroenterology & Hepatology.2022; 34(1): 69. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
Proteomic characterization of the natural history of chronic HBV infection revealed by tandem mass tag-based quantitative proteomics approach Zhen Xun, Xiaobao Yao, Chenggong Zhu, Yuchen Ye, Songhang Wu, Tianbin Chen, Yongbin Zeng, Caorui Lin, Bin Yang, Qishui Ou, Can Liu Materials Today Bio.2022; 15: 100302. CrossRef
Development and Validation of a Risk Score for Liver Cirrhosis Prediction in Untreated and Treated Chronic Hepatitis B An K Le, Hwai-I Yang, Ming-Lun Yeh, Mingjuan Jin, Huy N Trinh, Linda Henry, Anne Liu, Jian Q Zhang, Jiayi Li, Christopher Wong, Clifford Wong, Ramsey Cheung, Ming-Lung Yu, Mindie H Nguyen The Journal of Infectious Diseases.2021; 223(1): 139. CrossRef
Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir Jin Won Chang, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yeon Seok Seo, Han Ah Lee, Mi Na Kim, Yu Rim Lee, Seong Gyu Hwang, Kyu Sung Rim, Soon Ho Um, Won Young Tak, Young Oh Kweon, Soo Young Park, Seung Up Kim Journal of Viral Hepatitis.2021; 28(1): 95. CrossRef
Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B Hye Won Lee, Young Eun Chon, Beom Kyung Kim, Terry Cheuk-Fung Yip, Yee-Kit Tse, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Henry Lik-Yuen Chan, Sang Hoon Ahn European Journal of Internal Medicine.2021; 84: 68. CrossRef
Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach Robério Amorim de Almeida Pondé Molecular Biology Reports.2021; 48(1): 843. CrossRef
No influence of hepatic steatosis on the 3‐year outcomes of patients with quiescent chronic hepatitis B Jin Won Chang, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Viral Hepatitis.2021; 28(11): 1545. CrossRef
Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim Journal of Korean Medical Science.2021;[Epub] CrossRef
Breakthroughs and challenges in the management of pediatric viral hepatitis Emanuele Nicastro, Lorenzo Norsa, Angelo Di Giorgio, Giuseppe Indolfi, Lorenzo D'Antiga World Journal of Gastroenterology.2021; 27(20): 2474. CrossRef
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong Clinical and Molecular Hepatology.2021; 27(2): 273. CrossRef
Antiviral Therapy for Chronic HBV Infection With Persistently Normal Alanine Aminotransferase: Controversy and Consensus Jing Zhou, Fa-Da Wang, Meng-Lan Wang, Ya-Chao Tao, Dong-Bo Wu, Yun-Jian Sheng, Gui-Bao Xiao, Xue-Bin Chen, Xin Chen, En-Qiang Chen Frontiers in Medicine.2021;[Epub] CrossRef
Guidelines for Prevention and Treatment of Chronic Hepatitis B Guiqiang Wang, Zhongping Duan Journal of Clinical and Translational Hepatology.2021; 000(000): 000. CrossRef
Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients Zhen Xun, Can Liu, Qing-Qing Yu, Jin-Piao Lin, Jin-Lan Huang, Ting-Wen Yang, Wen-Nan Wu, Song-Hang Wu, Qi-Shui Ou Clinica Chimica Acta.2020; 502: 120. CrossRef
Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase Hye Won Lee, Eun Hwa Kim, Jinae Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Beom Kyung Kim Clinical and Translational Gastroenterology.2020; 11(3): e00140. CrossRef
Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients Gi‐Ae Kim, Seungbong Han, Gwang Hyeon Choi, Jonggi Choi, Young‐Suk Lim Alimentary Pharmacology & Therapeutics.2020; 51(11): 1169. CrossRef
Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune‐tolerant phase Han Ah Lee, Hyun Woong Lee, In Hee Kim, Soo Young Park, Dong Hyun Sinn, Jung Hwan Yu, Yeon Seok Seo, Soon Ho Um, Jung Il Lee, Kwan Sik Lee, Chang Hun Lee, Won Young Tak, Young Oh Kweon, Wonseok Kang, Yong‐Han Paik, Jin‐Woo Lee, Sang Jun Suh, Young Kul Jun Alimentary Pharmacology & Therapeutics.2020; 52(1): 196. CrossRef
Editorial: risk assessment for chronic hepatitis B patients in the immune tolerant phase—both definition and selection matter Yao‐Chun Hsu, Yen‐Tsung Huang Alimentary Pharmacology & Therapeutics.2020; 52(1): 213. CrossRef
Longitudinal Immune Phenotype Assessment and Serological Outcome in Foreign‐born Children With Chronic Hepatitis B Emanuele Nicastro, Benedetta Mangili, Vania Giacomet, Anna Rita Benincaso, Angelo Di Giorgio, Naire Sansotta, Annapaola Callegaro, Lorenzo D’Antiga Journal of Pediatric Gastroenterology and Nutrition.2020; 71(3): 381. CrossRef
Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee Clinical and Molecular Hepatology.2020; 26(4): 411. CrossRef
Immune-pathological phases of chronic Hepatitis B infections among Sudanese individuals towards personalization of management Shahd Mohamed Mustafa Abbas, Walla Saeed Eltahir Saeed, Osama Mohamed Musa, Mugtaba Elsamani Ahmed, Maria Mohamed H Satti, Brima Musa Younis, Ahmed Mudawi Musa, Eltahir Awad Gasim Khalil Journal of Human Virology & Retrovirology.2020; 8(1): 1. CrossRef
Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals Hye Won Lee, Seung Up Kim, Oidov Baatarkhuu, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Beom Kyung Kim Scientific Reports.2019;[Epub] CrossRef
Updated Treatment of Chronic Hepatitis B Eileen L. Yoon, Hyung Joon Yim The Korean Journal of Medicine.2019; 94(3): 252. CrossRef
Ex vivo Detection and Characterization of Hepatitis B Virus-Specific CD8+ T Cells in Patients Considered Immune Tolerant Pil Soo Sung, Dong Jun Park, Jung-Hee Kim, Ji Won Han, Eun Byul Lee, Gil Won Lee, Hee Chul Nam, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Eui-Cheol Shin, Su-Hyung Park, Seung Kew Yoon Frontiers in Immunology.2019;[Epub] CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2019; 25(2): 93. CrossRef
Are the Patients in the Immune Tolerant Phase of Chronic Hepatitis B far from Hepatocellular Carcinoma or Death? Nae-Yun Heo The Korean Journal of Gastroenterology.2019; 74(1): 66. CrossRef
Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations Won Hyeok Choe, Ki Jeong Kim, So Young Lee, Yu Min Choi, So Young Kwon, Jeong Han Kim, Bum Joon Kim World Journal of Gastroenterology.2019; 25(33): 4985. CrossRef
Phenotypes of Chronic Hepatitis B in Children From a Large North American Cohort Kathleen B. Schwarz, Manuel Lombardero, Adrian M. Di Bisceglie, Karen F. Murray, Philip Rosenthal, Simon C. Ling, Yona Keich Cloonan, Norberto Rodriguez‐Baez, Sarah Jane Schwarzenberg, Jay H. Hoofnagle, Jeffrey Teckman Journal of Pediatric Gastroenterology and Nutrition.2019; 69(5): 588. CrossRef
Natural History and Treatment Indications of Chronic Hepatitis B Dong Hyun Sinn The Korean Journal of Gastroenterology.2019; 74(5): 245. CrossRef
First
Prev
